IMS Pharmaceutical Pricing & Reimbursement Concise Guide: India

  • ID: 1408485
  • Report
  • Region: India
  • 49 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

India

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding

2. Pricing

  • Prescription Drugs
  • DPCO 2013 and 2016 Amendment Order
  • Fines for Excessive Pricing
  • Non-DPCO Products
  • Patented Drugs
  • Other Developments
  • Generic Drugs
  • Hospital Drugs
  • Centralised Purchasing Agency
  • State-level Procurement
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • Drug Reimbursement
  • Admission Procedures
  • State Schemes
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Changes in Reimbursement Status
  • NLEM
  • Changes in Reimbursement Prices
  • DPCO-controlled Products
  • Non-scheduled Formulations

4. Pharmacoeconomics

  • Pharmacoeconomic Requirements
  • Work with NICE; Moves to Establish HTA Body
  • National Health Policy

5. Price Build Up

  • Wholesalers
  • Margins
  • Background
  • Retail Pharmacies
  • Margins
  • Background
  • E-pharmacy
  • Generic Pharmacies
  • Hospital Pharmacies for Targeted Discounted Drugs
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Prescribing Controls
  • National Formulary
  • NLEM
  • Rational Usage and Monitoring
  • Generic Prescribing
  • E-prescribing
  • Generics
  • Generic Prescribing
  • Generic Pharmacies
  • Compulsory Licensing
  • Biosimilars
  • Rx-to-OTC Switches
  • Reverse Switch
  • Schedule H1
  • Parallel Trade

7. Future Developments

  • Outlook
  • New National Health Policy
  • Plans for Universal Coverage
  • Free Medicines Scheme
  • Consultation on Drug Regulation
  • Ongoing Pricing Reform

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll